SCHEMBL5543404

SCHEMBL5543404

O=CNCCc1cccc(OC(F)(F)F)c1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHRM2 P08172 2/20 0.58
CHRM1 P11229 2/20 0.58
CHRM3 P20309 2/20 0.58
CNR1 P21554 1/20 0.53
DAO P14920 1/20 0.50
TRPV1 Q8NER1 1/20 0.49
CETP P11597 2/20 0.45
CARM1 Q86X55 3/20 0.44
PRMT6 Q96LA8 3/20 0.44
MAPK14 Q16539 1/20 0.44
ROCK2 O75116 1/20 0.42
ROCK1 Q13464 1/20 0.42
KDM4E B2RXH2 1/20 0.42
MEN1 O00255 1/20 0.42
KMT2A Q03164 1/20 0.42
USP28 Q96RU2 1/20 0.41
USP25 Q9UHP3 1/20 0.41
KDM5A P29375 1/20 0.41
KDM4C Q9H3R0 1/20 0.41
KDM5B Q9UGL1 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5540089 0.92 CHRM2 (0.55) CHRM2CHRM1CHRM3CNR1DAO
SCHEMBL5544721 0.89 CHRM2 (0.46) CHRM2CHRM1CHRM3CNR1DAO
SCHEMBL3891414 0.85 CHRM2 (0.53) CHRM2CHRM1CHRM3CNR1DAO
SCHEMBL5537502 0.83 CHRM2 (0.62) CHRM2CHRM1CHRM3CNR1DAO
SCHEMBL3889241 0.81 EPHX2 (0.49) DAOTRPV1
SCHEMBL5539752 0.81 CHRM2 (0.44) CHRM2CHRM1CHRM3CNR1DAO
SCHEMBL5545576 0.81 CHRM2 (0.44) CHRM2CHRM1CHRM3CNR1DAO
SCHEMBL2473241 0.80 CHRM2 (0.66) CHRM2CHRM1CHRM3KDM4EMEN1
SCHEMBL22957905 0.80 CHRM2 (0.66) CHRM2CHRM1CHRM3CNR1DAO
SCHEMBL5543398 0.79 CNR1 (0.53) CHRM2CHRM1CHRM3CNR1DAO

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2570418-A2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-03-20 EP disclosed
EP-1555267-B1 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES OTSUKA PHARMA CO LTD (JP) 2013-01-16 EP disclosed
US-7262212-B2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-28 US disclosed
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-05-04 US disclosed
EP-1555267-A1 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2005-07-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles NR2C2, NR4A3, NR4A2 CHRM2 862/4885CHRM1 463/4885CHRM3 597/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.